Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
23 Apr 24
8-K
TransCode Therapeutics Reports 2023 Results; Provides Business Update
5 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 Jan 24
8-K
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
22 Jan 24
424B4
Prospectus supplement with pricing info
19 Jan 24
EFFECT
Notice of effectiveness
19 Jan 24
S-1/A
IPO registration (amended)
18 Jan 24
S-1/A
IPO registration (amended)
17 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
8-K
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
16 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
S-1
IPO registration
11 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
8 Jan 24
DEFA14A
Additional proxy soliciting materials
4 Jan 24
DEF 14A
Definitive proxy
18 Dec 23
PRE 14A
Preliminary proxy
8 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
8-K
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
4 Dec 23
424B5
Prospectus supplement for primary offering
1 Dec 23
8-K
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
8-K
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
27 Oct 23
424B5
Prospectus supplement for primary offering
26 Oct 23
8-K
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
24 Oct 23
8-K
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
28 Sep 23
424B4
Prospectus supplement with pricing info
27 Sep 23
EFFECT
Notice of effectiveness
26 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
S-1/A
IPO registration (amended)
22 Sep 23
CORRESP
Correspondence with SEC
22 Sep 23
CORRESP
Correspondence with SEC
22 Sep 23
CORRESP
Correspondence with SEC
22 Sep 23
Latest ownership filings
SC 13G/A
Medarova Zdravka
15 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Lind Global Fund II LP
7 Dec 23
SC 13D/A
Dudley Robert Michael
10 Oct 23
4
Thomas A Fitzgerald
2 Oct 23
4
Robert Michael Dudley
2 Oct 23
SC 13G
TANG CAPITAL PARTNERS LP
26 Sep 23
4
Robert Michael Dudley
22 Jun 23
SC 13D/A
Dudley Robert Michael
16 Jun 23
4/A
Robert Michael Dudley
14 Jun 23
4
Robert Michael Dudley
13 Jun 23
4
Erik Manting
19 May 23
4
Magda Marquet
19 May 23
4
Thomas A Fitzgerald
19 May 23
4
Robert Michael Dudley
19 May 23
4
Philippe Calais
19 May 23
4
Erik Manting
10 May 23
4
Magda Marquet
10 May 23
4
Philippe Calais
10 May 23
SC 13G/A
Medarova Zdravka
10 Feb 23
SC 13D
Dudley Robert Michael
20 Dec 22
SC 13G
Medarova Zdravka
20 Dec 22
SC 13G
Dudley Robert Michael
20 Dec 22
4
Thomas A Fitzgerald
14 Dec 22
4
Robert Michael Dudley
14 Dec 22
4
Zdravka Medarova
14 Dec 22
4
Zdravka Medarova
14 Dec 22
SC 13G/A
HIRSCHMAN ORIN
27 Oct 22
4
Robert Michael Dudley
16 Sep 22
4
Philippe Calais
22 Jun 22
4
Magda Marquet
22 Jun 22
4
Erik Manting
22 Jun 22
4
Thomas A Fitzgerald
17 Jun 22
4
Robert Michael Dudley
1 Jun 22
4
Thomas A Fitzgerald
2 Mar 22
SC 13G/A
HIRSCHMAN ORIN
11 Feb 22
4
Thomas A Fitzgerald
3 Feb 22
4
Robert Michael Dudley
3 Feb 22
SC 13G
HIRSCHMAN ORIN
21 Jul 21